Product Information
NEOMYC-BACIT-POLYMIX EYE OINT is a generic product labeled by Bausch & Lomb Incorporated, priced at $4.7024 per GM under NDC 24208078055. Its NADAC has been published 671 times since Nov 28, 2013.
FDA first approved this application on Oct 30, 1995. Its Orange Book therapeutic-equivalence code is AT.
Strength
400; 3.5; 10000 [USP'U]/g; mg/g; [USP'U]/g
Manufacturer
Bausch & Lomb IncorporatedNDC
24208078055
Classification
Generic
Dosage Form
OINTMENT
Route
OPHTHALMIC
Effective Date
9/23/2026
Active Ingredients
BACITRACIN ZINC; NEOMYCIN SULFATE; POLYMYXIN B SULFATEApproval Type
Generic (ANDA)
FDA Application
ANDA064064FDA Approved
10/30/1995
TE Code
AT
On Market Since
10/30/1995
Pharmacological Classes
Price Statistics
The NADAC for NEOMYC-BACIT-POLYMIX EYE OINT has been published 671 times since Nov 28, 2013, and over the history we have for it it has declined 56.6%. The table below summarizes its recorded NADAC range and movement.
| Current price | $4.7024 per GM |
|---|---|
| All-time high | $12.5571 (Feb 12, 2014) |
| All-time low | $4.5062 (Jul 22, 2026) |
| 52-week high | $5.0029 |
| 52-week low | $4.5062 |
| Median price | $7.6919 |
| Average price | $8.2391 |
| Largest weekly change | +69.1% (Nov 18, 2020) |
| Weeks tracked | 671 |
| Tracking since | Nov 28, 2013 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the Neomycin sulfate, Polymyxin B Sulfate and Bacitracin Zinc market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Bausch & Lomb Incorporated manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Neomycin sulfate, Polymyxin B Sulfate and Bacitracin Zinc market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Aminoglycoside Antibacterial class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of NEOMYC-BACIT-POLYMIX EYE OINT?
The current National Average Drug Acquisition Cost (NADAC) for NEOMYC-BACIT-POLYMIX EYE OINT, manufactured by Bausch & Lomb Incorporated, is $4.7024 per GM (NDC 24208078055), effective Sep 30, 2026.
How has the price of NEOMYC-BACIT-POLYMIX EYE OINT changed over time?
Over the history we have for it, the NADAC for NEOMYC-BACIT-POLYMIX EYE OINT has declined 56.6%. It has been tracked across 671 weekly CMS publications since Nov 28, 2013.
What are the highest and lowest recorded NADAC prices for NEOMYC-BACIT-POLYMIX EYE OINT?
Since Nov 28, 2013, the NADAC for NEOMYC-BACIT-POLYMIX EYE OINT has ranged from a low of $4.5062 (Jul 22, 2026) to a high of $12.5571 (Feb 12, 2014), with a median of $7.6919 per GM.
Are there cheaper alternatives to NEOMYC-BACIT-POLYMIX EYE OINT?
No other NADAC-published product currently shares the active ingredient and strength of NEOMYC-BACIT-POLYMIX EYE OINT in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures NEOMYC-BACIT-POLYMIX EYE OINT?
NEOMYC-BACIT-POLYMIX EYE OINT (NDC 24208078055) is labeled by Bausch & Lomb Incorporated, and CMS classifies it as a generic product.